MannKind Corporation Stock Nasdaq
Equities
US56400P2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 26 | MannKind CFO Binder to Retire in April, Names New CFO | MT |
Mar. 26 | MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024 | CI |
Financials (USD)
Sales 2024 * | 260M | Sales 2025 * | 313M | Capitalization | 1.13B |
---|---|---|---|---|---|
Net income 2024 * | 38M | Net income 2025 * | 73M | EV / Sales 2024 * | 3.41 x |
Net cash position 2024 * | 248M | Net cash position 2025 * | 273M | EV / Sales 2025 * | 2.76 x |
P/E ratio 2024 * |
31.7
x | P/E ratio 2025 * |
18.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.47% |
Latest transcript on MannKind Corporation
Managers | Title | Age | Since |
---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 47 | 16-03-13 |
Sanjay Singh
CTO | Chief Tech/Sci/R&D Officer | 57 | 22-09-30 |
Kevin Kaiserman
CTO | Chief Tech/Sci/R&D Officer | - | 20-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | 18-11-26 | |
Anthony Hooper
BRD | Director/Board Member | 69 | 19-12-31 |
Ronald Consiglio
BRD | Director/Board Member | 80 | 03-09-30 |
1st Jan change | Capi. | |
---|---|---|
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |